128 related articles for article (PubMed ID: 12853892)
1. Activity, pharmacokinetics and tissue distribution of TLC ELL-12 (liposomal antitumor ether lipid) in rats with transplantable, s.c. methylnitrosourea-induced tumors.
Bhamra R; Bolcsak LE; Ahmad I; Schupsky J; Roberts P; Stevens R; Cavanaugh C; Swenson CE
Anticancer Drugs; 2003 Jul; 14(6):481-6. PubMed ID: 12853892
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and disposition of TLC ELL-12 (liposomal antitumor ether lipid) in Sprague-Dawley rats.
Bhamra R; Bolcsak LE; Roberts P; Stevens R; Cavanaugh C; Swenson CE
Anticancer Drugs; 2003 Mar; 14(3):183-91. PubMed ID: 12634612
[TBL] [Abstract][Full Text] [Related]
3. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine.
Ahmad I; Filep JJ; Franklin JC; Janoff AS; Masters GR; Pattassery J; Peters A; Schupsky JJ; Zha Y; Mayhew E
Cancer Res; 1997 May; 57(10):1915-21. PubMed ID: 9157985
[TBL] [Abstract][Full Text] [Related]
4. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis.
Gajate C; Fonteriz RI; Cabaner C; Alvarez-Noves G; Alvarez-Rodriguez Y; Modolell M; Mollinedo F
Int J Cancer; 2000 Mar; 85(5):674-82. PubMed ID: 10699948
[TBL] [Abstract][Full Text] [Related]
5. Liposomal ET-18-OCH(3) induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling.
Cuvillier O; Mayhew E; Janoff AS; Spiegel S
Blood; 1999 Nov; 94(10):3583-92. PubMed ID: 10552970
[TBL] [Abstract][Full Text] [Related]
6. Modulation of chemical carcinogenesis in rats by alkyl lysophospholipids.
Berger MR; Schmähl D
Lipids; 1987 Nov; 22(11):935-42. PubMed ID: 3127647
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
Lubet RA; Steele VE; DeCoster R; Bowden C; You M; Juliana MM; Eto I; Kelloff GJ; Grubbs CJ
Carcinogenesis; 1998 Aug; 19(8):1345-51. PubMed ID: 9744527
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.
Sharkey EM; O'Neill HB; Kavarana MJ; Wang H; Creighton DJ; Sentz DL; Eiseman JL
Cancer Chemother Pharmacol; 2000; 46(2):156-66. PubMed ID: 10972486
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibitory effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine.
Peters AC; Ahmad I; Janoff AS; Pushkareva MY; Mayhew E
Lipids; 1997 Oct; 32(10):1045-54. PubMed ID: 9358430
[TBL] [Abstract][Full Text] [Related]
10. Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine.
Pushkareva MY; Wannberg SL; Janoff AS; Mayhew E
Cancer Immunol Immunother; 2000 Jan; 48(10):569-78. PubMed ID: 10630309
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of a new antitumor semisynthetic ether phospholipid, 14C-labeled plasmanyl-(N-acyl)ethanolamine, in mice bearing sarcoma Mc11.
Kára J; Zimakova NI; Serebryakova EA; Dĕdková V; Zolotaryov AE
J Cancer Res Clin Oncol; 1994; 120(11):662-7. PubMed ID: 7962042
[TBL] [Abstract][Full Text] [Related]
12. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.
Lubet RA; Gordon GB; Prough RA; Lei XD; You M; Wang Y; Grubbs CJ; Steele VE; Kelloff GJ; Thomas CF; Moon RD
Cancer Res; 1998 Mar; 58(5):921-6. PubMed ID: 9500451
[TBL] [Abstract][Full Text] [Related]
13. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells.
Gajate C; Mollinedo F
Curr Drug Metab; 2002 Oct; 3(5):491-525. PubMed ID: 12369895
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of methylnitrosourea (MNU) induced oxidative stress and carcinogenesis by orally administered bee honey and Nigella grains in Sprague Dawely rats.
Mabrouk GM; Moselhy SS; Zohny SF; Ali EM; Helal TE; Amin AA; Khalifa AA
J Exp Clin Cancer Res; 2002 Sep; 21(3):341-6. PubMed ID: 12385575
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.
Hassan M; Hassan Z; Nilsson C; Rehim MA; Kumlien S; Elfsson B; Kållberg N
Cancer Chemother Pharmacol; 1998; 42(6):471-8. PubMed ID: 9788573
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.
Tatsuta N; Suzuki N; Mochizuki T; Koya K; Kawakami M; Shishido T; Motoji N; Kuroiwa H; Shigematsu A; Chen LB
Cancer Chemother Pharmacol; 1999; 43(4):295-301. PubMed ID: 10071980
[TBL] [Abstract][Full Text] [Related]
17. Curcumin suppresses N-methyl-N-nitrosourea-induced photoreceptor apoptosis in Sprague-Dawley rats.
Emoto Y; Yoshizawa K; Uehara N; Kinoshita Y; Yuri T; Shikata N; Tsubura A
In Vivo; 2013; 27(5):583-90. PubMed ID: 23988891
[TBL] [Abstract][Full Text] [Related]
18. Intravenous vs. intraprostatic administration of N-methyl-N-nitrosourea to induce prostate cancer in rats.
Schleicher RL; Fallon MT; Austin GE; Zheng M; Zhang M; Dillehay DL; Collins DC
Prostate; 1996 Jan; 28(1):32-43. PubMed ID: 8545279
[TBL] [Abstract][Full Text] [Related]
19. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I
Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
[TBL] [Abstract][Full Text] [Related]
20. Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.
Lubet RA; Szabo E; Iwata KK; Gill SC; Tucker C; Bode A; Steele VE; Juliana MM; Nicastro HL; Grubbs CJ
Cancer Prev Res (Phila); 2013 May; 6(5):448-54. PubMed ID: 23531447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
